alexa Can Targeted/metabolic Therapy Outperform Standard Chemotherapy For Breast Cancer In The Post-op Adjuvant Setting? In Vitro Live Cell Analysis And Clinical Correlation In A Breast Cancer Patient
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd World Congress on Cancer Science & Therapy
October 21-23, 2013 DoubleTree by Hilton Hotel San Francisco Airport, CA, USA

Akbar Khan
Posters: J Cancer Sci Ther
DOI: 10.4172/1948-5956.S1.029
Abstract
The diabetes drug metformin has been extensively researched as an anticancer therapy. Existing data suggests it may have a role in prevention and also in treatment, as an adjuvant to other therapies. In a recent publication ( Individualizing Chemotherapy using the Anti-Diabetic Drug, Metformin, as an ?Adjuvant?: An Exploratory Study. J Cancer SciTher 5:120-125.) Khan and Bradford demonstrated the potential widespread role of metformin in cancer treatment using human cells in vitro . Metformin was also shown to potentiate the metabolic therapy dichloroacetate. A 51 year old patient with intraductal breast carcinoma requested ChemoFitTMlive cell chemo sensitivity testing at the time of lumpectomy. Based on this, it was determined that a combination of metformin + dichloroacetate outperformed various standard chemotherapy cocktails approved breast cancer treatment (in terms of % cell kill). The patient was treated with oral dichloroacetate + metformin for 3 months. The patient developed moderate peripheral neuropathy from the dichloroacetate and the therapy was otherwise well-tolerated. MainTrac TM circulating tumor cell counts were taken pre- and post-treatment. The patient achieved a surprising result: A reduction of circulating tumor cell count from 1050 cells per cc of blood to 50 cells per cc of blood (a 21x reduction). There was no nausea/vomiting, infection, hair loss, marrow injury, hepatic injury or renal injury, due to the non-toxic nature of the therapy. The routine use of ChemoFit TM assay, testing non-toxic drugs (e.g. metformin, dichloroacetate) alongside conventional chemotherapies, has the potential to revolutionize post-operative adjuvant therapy of breast and other cancers.
Biography
Akbar Khan completed his MD in 1992, and obtained certification in Family Medicine in 1994 (University of Toronto). His primary practice for the last 20 years has consisted of palliative medicine. Seven years ago he found the first private integrated cancer center of its kind in Canada (Medicor Cancer Centres Inc), and since 2007 he has researched and successfully used several non-toxic off-label cancer therapies. He has treated over 1300 patients with dichloroacetate and is now using the diabetes drug metformin extensively as an adjuvant to chemotherapy and other anticancer drugs. He has 3 publications in peer-reviewed journals to date.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords